Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4107219
Max Phase: Preclinical
Molecular Formula: C10H19NO4
Molecular Weight: 217.26
Molecule Type: Small molecule
Associated Items:
ID: ALA4107219
Max Phase: Preclinical
Molecular Formula: C10H19NO4
Molecular Weight: 217.26
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)CN1CC1CC1
Standard InChI: InChI=1S/C10H19NO4/c12-5-7-9(14)10(15)8(13)4-11(7)3-6-1-2-6/h6-10,12-15H,1-5H2/t7-,8+,9-,10-/m1/s1
Standard InChI Key: KWBAIPASFIBUNH-UTINFBMNSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 217.26 | Molecular Weight (Monoisotopic): 217.1314 | AlogP: -1.84 | #Rotatable Bonds: 3 |
Polar Surface Area: 84.16 | Molecular Species: NEUTRAL | HBA: 5 | HBD: 4 |
#RO5 Violations: 0 | HBA (Lipinski): 5 | HBD (Lipinski): 4 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 12.90 | CX Basic pKa: 8.49 | CX LogP: -1.72 | CX LogD: -2.84 |
Aromatic Rings: 0 | Heavy Atoms: 15 | QED Weighted: 0.45 | Np Likeness Score: 1.16 |
1. (2015) Method for the treatment of pompe disease using 1-deoxynojirimycin and derivatives, |
Source(1):